Literature DB >> 26386079

INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms.

Jason N Rosenbaum1, Zhenying Guo2, Rebecca M Baus2, Helen Werner2, William M Rehrauer2, Ricardo V Lloyd2.   

Abstract

OBJECTIVES: Neuroendocrine neoplasms (NENs) are heterogeneous neoplasms, which are sometimes malignant, although predicting metastasis is difficult. INSM1 is a transcription factor expressed transiently in embryonic neuroendocrine (NE) tissue, thought to coordinate termination of cell division with differentiation of NE and neuroepithelial cells. In adult tissues, INSM1 has been identified in multiple tumors of NE or neuroepithelial origin but has not been thoroughly investigated as a potential neoplastic marker.
METHODS: We evaluated INSM1 as a semiquantitative immunohistochemical (IHC) marker for NE and neuroepithelial neoplasms and as a quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) marker for gastrointestinal NENs (GI-NENs).
RESULTS: Using IHC, we found in normal adult tissue that INSM1 expression was highly restricted to nuclei of NE cells and tissues. INSM1 was not detected in any adult nonneoplastic, non-NE tissue. In neoplastic tissue, INSM1 was detectable by IHC in 88.3% of 129 NEN specimens. In contrast, INSM1 was detected by IHC in only one of 27 neoplasms without a neuroepithelial or NE component. Using qRT-PCR, we evaluated INSM1 gene expression in 113 GI-NEN specimens.
CONCLUSIONS: INSM1 expression was significantly increased in neoplastic vs nonneoplastic tissue. Furthermore, among midgut GI-NENs, neoplasms with known metastases showed significantly higher expression than those that had not yet metastasized. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Cancer; IHC; INSM1; NEN; Neuroendocrine; Neuroepithelial

Mesh:

Substances:

Year:  2015        PMID: 26386079     DOI: 10.1309/AJCPGZWXXBSNL4VD

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  28 in total

1.  Insulinoma-associated protein 1(INSM1) is a superior marker for the diagnosis of gastroenteropancreatic neuroendoerine neoplasms: a meta-analysis.

Authors:  Qinghui Zhang; Jiahuang Huang; Yajun He; Runze Cao; Jianchang Shu
Journal:  Endocrine       Date:  2021-05-22       Impact factor: 3.633

Review 2.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

Review 3.  Insulinoma-Associated-1: From Neuroendocrine Tumor Marker to Cancer Therapeutics.

Authors:  Chiachen Chen; Abner L Notkins; Michael S Lan
Journal:  Mol Cancer Res       Date:  2019-05-21       Impact factor: 5.852

4.  INSM1 Expression Is Frequent in Primary Central Nervous System Neoplasms but Not in the Adult Brain Parenchyma.

Authors:  Heather M Ames; Lisa M Rooper; John J Laterra; Charles G Eberhart; Fausto J Rodriguez
Journal:  J Neuropathol Exp Neurol       Date:  2018-05-01       Impact factor: 3.685

5.  INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma.

Authors:  Akihiko Yoshida; Naohiro Makise; Susumu Wakai; Akira Kawai; Nobuyoshi Hiraoka
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

6.  Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.

Authors:  Madhuchhanda Roy; Darya G Buehler; Ranran Zhang; Michael L Schwalbe; Rebecca M Baus; M Shahriar Salamat; Ricardo V Lloyd; Jason N Rosenbaum
Journal:  Endocr Pathol       Date:  2019-03       Impact factor: 3.943

Review 7.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

Review 8.  Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Andrew M Bellizzi
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495

9.  A promoter-driven assay for INSM1-associated signaling pathway in neuroblastoma.

Authors:  Chiachen Chen; Michael S Lan
Journal:  Cell Signal       Date:  2020-09-20       Impact factor: 4.315

10.  Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes.

Authors:  Wei Zhang; Luc Girard; Yu-An Zhang; Tomohiro Haruki; Mahboubeh Papari-Zareei; Victor Stastny; Hans K Ghayee; Karel Pacak; Trudy G Oliver; John D Minna; Adi F Gazdar
Journal:  Transl Lung Cancer Res       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.